Dosages

Nafarelin is used to treat precocious puberty at a dosage of 1,600 to 1,800 μg per day.^[2] The 1,600 μg/day dosage is achieved by two sprays (400 μg total) into each nostril in the morning (four sprays, 800 μg total) and two sprays (400 μg total) into each nostril in the evening (four sprays, 800 μg total).^[2] If 1,600 μg/day is insufficient for adequate pubertal suppression, the 1,800 μg/day dosage can be used instead. This is achieved by three sprays (600 μg total) into alternating nostrils three times per day (nine sprays per day total).^[2] When administering the sprays, the head should be tilted back slightly and 30 seconds should elapse between each spray.^[2] A bottle of nafarelin nasal spray (brand name Synarel) lasts for about 7 days at a dosage of 1,600 μg/day.^[2]

Nafarelin is used to treat endometriosis at lower dosages of 400 to 800 μg per day.^[2] This is achieved by one or two sprays (200 or 400 μg total) into alternating nostrils once in the morning and once in the evening (two to four sprays per day total).^[2] A bottle of nafarelin nasal spray (brand name Synarel) lasts for about 30 days at a dosage of 400 μg/day.^[2]

Available forms

Nafarelin is available in the form of a 0.2% nasal spray for use one, two, or three times per day.^[20][2][1] Each bottle of nafarelin nasal spray (brand name Synarel) contains about 60 sprays delivering approximately 200 μg nafarelin in 100 μL solution per actuation.^[2] Nafarelin is not available for use by any other routes than intranasal administration.^[21]

Pharmacodynamics

Nafarelin is a GnRH agonist, or an agonist of the GnRH receptor, the biological target of GnRH.^[1][2] It works by continuously activating the GnRH receptor, which results in profound desensitization of the receptor such that it becomes non-functional.^[1][2] As a result, nafarelin suppresses the GnRH-induced secretion of the gonadotropins, luteinizing hormone and follicle-stimulating hormone, from the pituitary gland.^[1][2] This, in turn, results in profound suppression of gonadal sex hormone production, as well as reversible suppression of fertility.^[1][2]

Pharmacokinetics

The bioavailability of nafarelin with intranasal administration is 2.8% on average, with a range of 1.2 to 5.6%.^[2] The plasma protein binding of nafarelin is 80%.^[2] It is metabolized primarily by peptidases and not by cytochrome P450 enzymes.^[2] The elimination half-life of nafarelin is 2.5 to 3.0 hours by intranasal administration, whereas the half-life of nafarelin and its metabolites by subcutaneous injection is 85.5 hours.^[2] Nafarelin is eliminated 44 to 55% in urine and 18.5 to 44.2% in feces.^[2]

Generic names

Nafarelin is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while nafaréline is its DCFTooltip Dénomination Commune Française and nafarelin acetate is its USANTooltip United States Adopted Name, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name.^{[26][12][27][11]} It is also known by its former developmental code name RS-94991 or RS-94991-298.^{[26][12][27][11]}

Brand names

The major brand names of nafarelin are Synarel and Synarela.^[12][11] It has also been marketed under a number of other brand names including Synrelin, Synrelina, Nafarelil 0.2%, and Nasanyl 0.2%.^[12][11]

Availability

Nafarelin is available widely throughout the world, including in the United States, Canada, the United Kingdom, Ireland, other European countries, Australia, Israel, Argentina, Brazil, Mexico, and Japan.^[12][11]